AbbVie (NYSE:ABBV) announced Thursday its experimental therapy Tavapadon for Parkinson's disease reached the primary endpoint in a Phase 3 trial, indicating a statistically significant improvement ...
AbbVie said tavapadon met the primary endpoint in the pivotal Phase 3 fixed-dose monotherapy trial, showing a statistically significant improvement in certain measures of the disease from baseline ...